PRINCETON, NJ – Feb. 25, 2020 – Certara’s Simcyp Division Acquires Modeling and Simulation Platform for Neurodegenerative Diseases from In Silico Biosciences, Inc. Acquisition will spur the development of new drugs to treat complex neurodegenerative conditions, including Alzheimer’s and Parkinson’s disease.

PRINCETON, NJ – Feb. 10, 2020 – Arvinas Selects Certara to Advance Speed and Efficiency of its Targeted Protein Degradation Research

PRINCETON, NJ – Jan. 23, 2020 – Certara today reported that more than 90% of novel new drug approvals by the US Food and Drug Administration (FDA) in 2019 were supported by Certara software or services.

PRINCETON, NJ – Jan. 8, 2020 – Certara’s Simcyp® Simulator’s MechDermA™ model provided safety label claim and pediatric dosing information without the need for testing in clinical patients for a topical drug product.

November 21, 2019 PK Submit generates PK CDISC domains automatically, allowing sponsors to file regulatory submissions faster, while also improving data organization and compliance

Oct 18, 2019 Sessions feature physiologically-based pharmacokinetic (PBPK), pharmacokinetic/pharmacodynamic (PK/PD) and quantitative systems pharmacology (QSP) modeling and simulation

Oct 16, 2019 The most influential scientific research consortium of its kind: 37 biopharmaceutical companies work in a pre-competitive environment to advance PBPK modeling and simulation, progress new drug and biologics research, create new regulatory frontiers, foster ongoing modeling and simulation education, and present industry awards